Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis
Knee Osteoarthritis
About this trial
This is an interventional treatment trial for Knee Osteoarthritis focused on measuring platelet-rich plasma, cross-linked hyaluronic acid, knee osteoarthritis
Eligibility Criteria
Inclusion Criteria: Tibiofemoral knee osteoarthrosis according to ACR criteria Tibiofemoral knee osteoarthrosis grade 3-4 according to the Kellgren & Lawrence grading scale, as defined on knee radiographs (less than 3 months old: face view, schuss view, profile and patellar axial view at 30°) Symptomatic knee osteoarthrosis as evidenced by pain on walking (WOMAC A1 assessed in the last 24 hours on a scale of 0 to 100 mm: 50 ≤ DM 90 or reduced joint function (WOMAC C total score assessed or within the previous 24 hours based on a scale of 0-100-mm: 50 ≤ WOMAC C ≤ 90) Patient able to understand the requirements of the trial and who has signed a free and informed consent prior to study entry Patient able to read and understand the written instructions Patient able to complete the self-assessment questionnaires Exclusion Criteria: Tibiofemoral knee osteoarthrosis grade I or II according to the Kellgren and Lawrence grading scale Knee surgery planned in the next 6 months Patient affected by autoimmune disease (rheumatoid arthritis, lupus, Hashimoto's disease and Bechterew's syndrome) Chronic inflammatory rheumatism other than arthritis (polyarthrosis, etc.) Patient affected by a knee infection in the past 6 months Clinical signs of local knee inflammation (redness or warmth of the knee joint) Last PRP or PRP/HA injection received in the last year Last viscosupplementation received in the past 6 months Last corticosteroid injection received in the past 3 months Use of gluco-corticosteroids (except inhaled) and level III analgesics in the last 3 months and non-steroidal anti-inflammatory drug in the last 2 weeks Treatment with AAAL initiated within the last 6 months History of allergy to hyaluronic acid Hematologic or clotting disorders (thrombocytopenia) or blood coagulation (deficit-blood dyscrasia) Patients with coagulation times outside the reference values Anemia (HGB<10 g/dl) Venous or lymphatic stasis in the corresponding limb Malignant diseases (especially bone or haematological) Patients with serious, no-stabilized pathologies (cardiovascular disease, active peptic ulcer, digestive hemorrhage) Acute infection Patients with cancer or with an immuno-deprassant treatment ongoing Participation in another clinical trial for osteoarthritis of the knee in the last year Participation in another clinical trial, ongoing or completed within the last 3 months Patient unable to comply with the constraints of the protocol, in particular a patient whose mental state does not allow him/her to patient's mental state does not allow him/her to understand the nature, objectives and possible consequences of the study Pregnant or breastfeeding women or women who expect to become pregnant during the study Any other reason which may interfere with the proper conduct of the study, in the investigator's opinion
Sites / Locations
- Hopital Le Bocage ChruRecruiting
- Hopital LapeyronieRecruiting
- Clinique Medipole Garonne, Radiologie Interventionnelle 45 Rue GironisRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Placebo Comparator
RegenMatrix-PRP-XLHA
Hylan G-F 20
Placebo
Patients randomized in this group will receive a single injection of a combination of platelet-rich plasma plus cross-linked hyaluronic acid, prepared with the medical device RegenMatrix.
Patients randomized in this group will receive a single injection of cross-linked hyaluronic acid Hylan G-F 20 (Synvisc-One®).
Patients randomized in this group will receive a single injection of saline solution (0.9% NaCl)